TG Therapeutics, Inc.
Financials
Valuation Metrics
TG Therapeutics, Inc.'s Market Cap is $7.07B. At end of 2025 it was $4.26B. Ranked #1153 of 3,112 in US market (top 37%), #375 of 1,445 on NASDAQ (top 26%), #62 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $7.07B | US#1,153/3,112 Sec#62/269 |
| Revenue | $700M | US#2,170/3,112 Sec#68/269 |
| Net Income | $462M | US#855/3,112 Sec#33/269 |
| Total Assets | $1.53B | US#2,222/3,112 Sec#63/269 |
| Net Assets | $583M | US#2,136/3,112 Sec#96/269 |
| Employees | 399 | US#1,381/3,112 Sec#49/269 |
| Value | ||
| P/E | 15.30x | US#699/3,112 Sec#27/269 |
| P/B | 12.12x | US#2,675/3,112 Sec#212/269 |
| PEG | 0.05x | US#124/3,112 Sec#7/269 |
| P/S | 10.09x | US#2,658/3,112 Sec#122/269 |
| EV/EBITDA | 49.13x | US#2,350/3,112 Sec#78/269 |
| FCF Yield | -0.20% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | 79.21% | US#58/3,112 Sec#9/269 |
| ROA | 30.21% | US#26/3,112 Sec#6/269 |
| Op. Margin | 21.35% | US#833/3,112 Sec#39/269 |
| Revenue Growth | 69.56% | US#208/3,112 Sec#43/269 |
| Earnings Growth | 290.85% | US#146/3,112 Sec#8/269 |
| Financial Health | ||
| Debt Ratio | 162.18% | US#1,573/3,112 Sec#190/269 |
| Total Debt | $754M | US#1,617/3,112 Sec#51/269 |
| FCF | $-14M | US#2,353/3,112 Sec#90/269 |
| Cash | $442M | US#1,152/3,112 Sec#62/269 |
| Current Ratio | 5.81x | US#413/3,112 Sec#131/269 |
| Net Debt/EBITDA | 2.07x | US#1,402/3,112 Sec#62/269 |
| Performance | ||
| 1Y Return | 31.84% | US#591/3,112 Sec#107/269 |
| 1M Return | -13.39% | US#2,758/3,112 Sec#192/269 |
| From 52W High | -22.14% | US#1,818/3,112 Sec#119/269 |
| 1Y MDD | -34.12% | US#1,644/3,112 Sec#106/269 |
| Trading | ||
| Volume | 6,404,895 shares | US#287/3,112 Sec#22/269 |
| Trading Value | $309M | US#343/3,112 Sec#17/269 |
| Per Share | ||
| EPS | $3.13 | US#961/3,112 Sec#29/269 |
| BPS | $4.53 | US#2,270/3,112 Sec#139/269 |
Company Info
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.